- $118.57m
- $57.63m
- $194.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.71 | ||
| Price to Tang. Book | 3.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -191.26% | ||
| Return on Equity | -70.71% | ||
| Operating Margin | -15.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 92.88 | 119.03 | 152.55 | 154.82 | 194.06 | 207.64 | 245.22 | 39.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.
Directors
- Justin Schreiber CHM (38)
- Alexander Mironov PRE (41)
- Marc Benathen CFO (41)
- Sean Fitzpatrick CEX (38)
- Brad Roberts COO (40)
- Dennis Wijnker CTO
- Maria Stan CAO (47)
- Stefan Galluppi CMO (34)
- Eric Yecies CCO (43)
- Joseph DiTrolio OTH (70)
- Nicholas Alvarez OTH (29)
- Corey Deutsch OTH (27)
- Bryant Hussey OTH (45)
- Anthony Puopolo OTH (49)
- Naveen Bhatia DRC
- Roberto Simon IND (46)
- John Strawn IND (60)
- Bertrand Velge IND (62)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 21st, 1994
- Public Since
- July 11th, 2001
- No. of Shareholders
- 318
- No. of Employees
- 347
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 48,200,837
- Address
- 236 Fifth Avenue, Suite 400, NEW YORK, 10001
- Web
- https://lifemd.com/
- Phone
- +1 3026587581
- Contact
- Yvonne Briggs
- Auditors
- PricewaterhouseCoopers LLP
Latest News for LFMD
Upcoming Events for LFMD
Q3 2026 LifeMD Inc Earnings Release
Q4 2026 LifeMD Inc Earnings Release
Similar to LFMD
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anbio Biotechnology
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
FAQ
As of Today at 03:48 UTC, shares in LifeMD are trading at $2.46. This share price information is delayed by 15 minutes.
Shares in LifeMD last closed at $2.46 and the price had moved by -61.74% over the past 365 days. In terms of relative price strength the LifeMD share price has underperformed the S&P500 Index by -67.25% over the past year.
The overall consensus recommendation for LifeMD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLifeMD does not currently pay a dividend.
LifeMD does not currently pay a dividend.
LifeMD does not currently pay a dividend.
To buy shares in LifeMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.46, shares in LifeMD had a market capitalisation of $118.57m.
Here are the trading details for LifeMD:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LFMD
Based on an overall assessment of its quality, value and momentum LifeMD is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in LifeMD is $8.13. That is 230.49% above the last closing price of $2.46.
Analysts covering LifeMD currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LifeMD. Over the past six months, its share price has underperformed the S&P500 Index by -44.78%.
As of the last closing price of $2.46, shares in LifeMD were trading -34.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The LifeMD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
LifeMD's management team is headed by:
- Justin Schreiber - CHM
- Alexander Mironov - PRE
- Marc Benathen - CFO
- Sean Fitzpatrick - CEX
- Brad Roberts - COO
- Dennis Wijnker - CTO
- Maria Stan - CAO
- Stefan Galluppi - CMO
- Eric Yecies - CCO
- Joseph DiTrolio - OTH
- Nicholas Alvarez - OTH
- Corey Deutsch - OTH
- Bryant Hussey - OTH
- Anthony Puopolo - OTH
- Naveen Bhatia - DRC
- Roberto Simon - IND
- John Strawn - IND
- Bertrand Velge - IND